aTYR PHARMA INC (ATYR) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2020-09-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2020-09-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2020-09-30..
Borrowing debt
Overview →Financial period ending 2020-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2020-09-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2020-09-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2020-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 3.06M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 36.15M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 41.64M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | (m) | (m) | $3.06M | (m) | (m) | $36.15M | $41.64M | (m) |
| 2020-06-30 | (m) | (m) | $4.98M | (m) | (m) | $41.43M | $47.56M | (m) |
| 2020-03-31 | (m) | (m) | $6.87M | (m) | (m) | $49.83M | $54.45M | (m) |
| 2019-12-31 | (m) | (m) | $8.74M | (m) | (m) | $31.14M | $36.19M | (m) |
| 2019-09-30 | (m) | (m) | $7.84M | $2.74M | (m) | $38.06M | $43.74M | (m) |
| 2019-06-30 | (m) | (m) | $7.82M | $4.60M | (m) | $42.40M | $48.76M | (m) |
| 2019-03-31 | (m) | (m) | $7.79M | $6.44M | (m) | $43.02M | $49.91M | (m) |
| 2018-12-31 | (m) | (m) | $7.77M | $8.26M | (m) | $49.55M | $52.75M | (m) |
| 2018-09-30 | (m) | (m) | $7.74M | $10.06M | (m) | $55.96M | $59.77M | (m) |
| 2018-06-30 | (m) | (m) | $7.72M | $11.85M | (m) | $64.33M | $68.31M | (m) |
| 2018-03-31 | (m) | (m) | $7.03M | $12.95M | (m) | $74.10M | $78.47M | (m) |
| 2017-12-31 | (m) | (m) | $5.01M | $14.72M | (m) | $85.12M | $89.36M | (m) |
| 2017-09-30 | (m) | (m) | $2.27M | $12.48M | (m) | $90.38M | $94.49M | (m) |
| 2017-06-30 | (m) | (m) | $2.79M | $11.79M | (m) | $57.22M | $61.47M | (m) |
| 2017-03-31 | (m) | (m) | $1.09M | $8.48M | (m) | $61.93M | $65.73M | (m) |
| 2016-12-31 | (m) | (m) | $339.00K | $9.20M | (m) | $72.15M | $80.52M | (m) |
| 2015-12-31 | (m) | (m) | $3.37M | $1.78M | (m) | $95.53M | $129.68M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |